In June 2011, CTSW closed a $30 million financing by its client, Cowen Healthcare Royalty Partners, L.P., of Zogenix, Inc. (Nasdaq: ZGNIX), a California-based pharmaceutical company that develops products for the treatment of central nervous system disorders and pain. Repayment of the financing is backed by revenues derived primarily from Zogenix's first commercial product, SUMAVEL DosePro, a Needle-free Delivery System for the acute treatment of migraine and cluster headaches. CTSW negotiated the financing documents, intercreditor arrangements with Zogenix's senior lender, and equity investment documents. Cowen Healthcare Royalty Partners is a global healthcare investment firm with more than $1.2 billion under management and invests principally in commercial-stage healthcare companies and products through drug royalty acquisitions and structured financings.
